Food and Drug AdministrationBethesda, MD, United States
FDA Safety Evaluator, Division of Pharmacovigilance
1822: The Food and Drug Administration’s (FDA’s) Safety Surveillance of Baricitinib and Tocilizumab for COVID-19 (Disclaimer: This Abstract Reflects the Views of the Authors and Not Necessarily Those of the US FDA)
Tuesday, November 14, 20239:00 AM – 11:00 AM PT
Disclosure information not submitted.